Published: December 5th 2024 | Updated: December 6th 2024 FDA Approves Durvalumab for Treatment of Adults Patients With LS-SCLC Gillian McGovern, Assistant Editor December 5th 2024 FDA Grants Breakthrough Therapy Designation to Sac-TMT for Previously Treated NSCLC Gillian McGov...
Against this backdrop, SCLC treatment is on the verge of a breakthrough, with the recent development of new treatments that could improve the cure rate for patients with limited-stage small cell lung cancer (LS-SCLC). AstraZeneca's anti-PD-L1 immuno-oncology drug Imfinzi (durvalumab) demonstr...
A new drug application has been resubmitted to the FDA for the combination of camrelizumab and rivoceranib as a first-line treatment for unresectable hepatocellular carcinoma, following a complete response letter in May 2024. Read More Tremelimumab Plus Durvalumab Turns Heads With Updated Five-Yea...
Additionally, arm 6 of the BEGONIA study (NCT03742102) is exploring the treatment for patients with triple-negative breast cancer in combination with the PD-L1 inhibitor durvalumab (Imfinzi). References Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan (T-DXd) versus treatment of p...
Dr Westin on the FDA Approval of Durvalumab Plus Chemo in dMMR Endometrial Cancer Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study ...
durvalumab (Imfinzi) CTLA-4 inhibitors CTLA-4 inhibitors work slightly differently. They trigger the T cells to search actively for cancer cells and destroy them. Only one typeTrusted Source of CTLA-4, ipilimumab (Yervoy), has FDA approval. Doctors may use it alongside other drugs to treat ad...
Lately, TOPAZ-1 trial showed Durvalumab plus GEMCIS provided significant survival benefits for patients with locally advanced or metastatic BTC compared to GEMCIS chemotherapy (median OS: 12.8 months versus 11.5 months).8 Thus, this regimen also was recommended as one of preferred first-line ...
September 1, 2011 — The US Food and Drug Administration (FDA) recently granted accelerated approval to crizotinib (Xalkori, Pfizer) for the treatment of patients with advanced-stage nonsmall-cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive. A companion diagnostic test ...
Envafolimab is used in solid cancers, including non-small cell lung cancer, because, like Durvalumab and Atezolizumab (Supplementary Materials, Table S1-S2), it targets the protein programmed cell death-ligand 1 (PD-L1).Citation425–429 An example of a combination of a nanobody with a ...
2. FDA approves pembrolizumab for metastatic small cell lung cancer. FDA. June 17, 2019. Accessed March 2, 2021. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-metastatic-small-cell-lung-cancer